Equities analysts predict that Aemetis, Inc. (NASDAQ:AMTX – Get Rating) will report $55.52 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aemetis’ earnings. The highest sales estimate is $59.56 million and the lowest is $50.00 million. Aemetis reported sales of $42.81 million during the same quarter last year, which would suggest a positive year over year growth rate of 29.7%. The business is scheduled to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Aemetis will report full year sales of $251.58 million for the current fiscal year, with estimates ranging from $213.00 million to $288.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $395.05 million, with estimates ranging from $374.00 million to $419.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Aemetis.
Aemetis (NASDAQ:AMTX – Get Rating) last posted its earnings results on Thursday, March 10th. The specialty chemicals company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.24. The firm had revenue of $64.36 million during the quarter, compared to analyst estimates of $55.87 million. During the same quarter in the previous year, the business posted ($0.68) earnings per share.
Shares of AMTX stock opened at $9.13 on Friday. Aemetis has a 12-month low of $7.88 and a 12-month high of $23.33. The company has a market capitalization of $311.42 million, a P/E ratio of -5.67 and a beta of -0.22. The firm has a 50-day moving average price of $11.81 and a 200 day moving average price of $13.61.
In related news, Director John R. Block sold 55,165 shares of the business’s stock in a transaction dated Monday, March 14th. The stock was sold at an average price of $12.12, for a total value of $668,599.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. 14.65% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in AMTX. Royal Bank of Canada boosted its position in shares of Aemetis by 2,069.1% during the second quarter. Royal Bank of Canada now owns 7,592 shares of the specialty chemicals company’s stock valued at $85,000 after buying an additional 7,242 shares during the last quarter. Bank of America Corp DE purchased a new position in Aemetis during the 2nd quarter valued at approximately $466,000. Wells Fargo & Company MN boosted its holdings in shares of Aemetis by 1,396.7% in the 2nd quarter. Wells Fargo & Company MN now owns 48,255 shares of the specialty chemicals company’s stock worth $539,000 after purchasing an additional 45,031 shares during the period. SG Americas Securities LLC purchased a new position in shares of Aemetis in the 3rd quarter worth approximately $307,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Aemetis by 96.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 41,248 shares of the specialty chemicals company’s stock worth $754,000 after acquiring an additional 20,263 shares during the last quarter. Hedge funds and other institutional investors own 51.69% of the company’s stock.
Aemetis Company Profile (Get Rating)
Aemetis, Inc operates as a renewable natural gas and fuels, and byproducts company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products.
- Get a free copy of the StockNews.com research report on Aemetis (AMTX)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.